{
  "subset": "indication",
  "disease": "Gastrointestinal epithelial barrier disorders",
  "relation": "indication",
  "gold_drugs": [
    "teduglutide"
  ],
  "seeds_initial": [
    "Infliximab",
    "Mesalazine",
    "Budesonide",
    "Azathioprine",
    "Adalimumab",
    "Tacrolimus",
    "Natalizumab",
    "Vedolizumab",
    "Methotrexate",
    "Ustekinumab",
    "5-Aminosalicylic Acid",
    "Oral Corticosteroids"
  ],
  "seed_history": [
    [
      "Infliximab",
      "Mesalazine",
      "Budesonide",
      "Azathioprine",
      "Adalimumab",
      "Tacrolimus",
      "Natalizumab",
      "Vedolizumab",
      "Methotrexate",
      "Ustekinumab",
      "5-Aminosalicylic Acid",
      "Oral Corticosteroids"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "score": 0.64,
        "graph_snapshot_ref": "GE_H1_round3",
        "key_assumptions": [
          "良好疗效的已知治疗药物",
          "潜在不良反应可能会抵消效益"
        ],
        "caveats": [
          "不良反应的风险尚需进一步验证"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_mesalazine",
          "name": "Mesalazine"
        },
        "score": 0.64,
        "graph_snapshot_ref": "GE_H2_round3",
        "key_assumptions": [
          "相关文献支持其用于该表型",
          "潜在不良反应可能会抵消效益"
        ],
        "caveats": [
          "不良反应的风险尚需进一步验证"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        },
        "score": 0.63,
        "graph_snapshot_ref": "GE_H3_round3",
        "key_assumptions": [
          "临床应用常见，具有相似用途",
          "潜在不良反应可能会抵消效益"
        ],
        "caveats": [
          "不良反应的风险尚需进一步验证"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Phenotype (Gastrointestinal epithelial barrier disorders)",
          "reason": "支持关系的存在，但需克服不良反应风险带来的挑战"
        }
      ],
      "remaining_gaps": [
        "未能清晰识别不良反应的具体机制及其对治疗效果的影响"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "为多种候选药物在特定表型中治疗效果提供了文献支持"
        },
        {
          "round": 2,
          "seeds": [
            "E",
            "F"
          ],
          "impact_summary": "加强了药物之间的比较与风险评估"
        }
      ],
      "lessons": [
        "确保对不良反应的风险进行全面评估，避免潜在的干扰",
        "深入研究不同药物的作用机制以辨别其效用"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "聚焦于药物疗效和潜在不良反应的相互影响"
      },
      {
        "role": "Skeptic",
        "patch": "提供不良反应的详细机制分析"
      },
      {
        "role": "Explorer",
        "patch": "探索新候选药物及其特殊机制以提高疗效"
      }
    ],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that could be indicated for the rare disease 'Gastrointestinal epithelial barrier disorders'. Return only names.\n\n# Prior guidance for Explorer:\n- 探索新型药物的潜在机制与风险，避免同质化\n\n# Heuristics:\n- When 炎症性肠病: then 评估各药物的长短期风险效应\n- When 药物作用机制: then 识别每种治疗方案的独特性并探索替代选项"
}